The Agency for Healthcare Research and Quality (AHRQ) has published a report on the definition of treatment-resistant depression (TRD), and the absence of a consensus definition seems to inhibit efforts to deal with a condition that imposes as much as $48 billion in societal costs each year in the U.S., a figure certain to rise as the opioid epidemic plays out.